IL1B and Sepsis: Despite the remarkable success in preclinical models, most anti-inflammatory therapies targeting cytokine storms (such as anti-TNF-α, anti-IL-1β, and anti-endotoxin agents) have failed to significantly reduce mortality in large Phase 3 sepsis clinical trials.